FDA approves larger vial of Recothrom
ZymoGenetics said this morning that the FDA has agreed to allow the company to sell a larger-sized vial of the company's Recothrom treatment.
View ArticleRecothrom’s April sales
Kevin DeGeeter, an analyst at Oppenheimer & Co., put out a report today saying that Recothrom, ZymoGenetics' treatment to stop bleeding during surgery, had $92,589 in April sales, substantially...
View ArticleGilead Sciences drug awaits word from the FDA
Could three drugs developed in Seattle be approved by the Food and Drug Administration this year?
View ArticleMost influential in biotech: Bruce Carter
Second in a series. I asked seven of the top biotech leaders in the city to name three colleagues who they thought were the most influential players in the industry here. This week, I'll showcase the...
View ArticleZymoGenetics inks $100 million financing deal
Looking to strengthen its financial position, Seattle's ZymoGenetics said Monday it had reached a deal that will allow it to borrow up to $100 million over the next year-and-a-half.
View ArticleTransactions in the works at ZymoGenetics?
During yesterday's ZymoGenetics conference call to announce the company's $100 million financing deal, executives repeatedly referred to "transactions" or "business development objectives" in the works...
View ArticleWhat to watch for during earnings season
It's earnings season -- and here's a preview of the top storylines I'll be following on the blog.
View ArticleJune Recothrom sales miss forecast
Next week, ZymoGenetics will report second-quarter sales numbers for Recothrom, its treatment to control bleeding during surgery.
View ArticleRecothrom’s sales for the quarter fall short
Updated with my story for Wednesday's paper
View ArticleZymoGenetics’ Bruce Carter on Recothrom
On Tuesday, ZymoGenetics underwhelmed Wall Street for the second straight quarter with lackluster sales numbers for its first drug, Recothrom. Read my story on that news here. After the company's...
View ArticleAnalysts cut Recothrom sales forecasts
A day after ZymoGenetics reported weak second-quarter Recothrom sales, several analysts are cutting their 2008 Recothrom sales estimates.
View ArticleA slowdown in sales of Recothrom’s rival?
Last Tuesday, I wrote about Recothrom's sales for June.
View ArticleSales of Recothrom rival drop
King Pharmaceuticals said today that sales of Thrombin-JMI, which directly competes with ZymoGenetics' Recothrom, dropped in the second quarter.
View ArticleCompetitor says Recothrom in third place
In the market for thrombin, a protein used to control bleeding during surgery, ZymoGenetics' Recothrom is in third place, according to a competitor.
View ArticleStories to watch: ZGEN and SGEN
[Note: My time at the Seattle Post-Intelligencer is up, so this blog is no longer being updated. Please e-mail margaretsantjer@seattlepi.com with any life sciences related story ideas or news]
View Article
